Eli Lilly and Company (NYSE:LLY) Shares Sold by Cumberland Partners Ltd

Cumberland Partners Ltd reduced its position in shares of Eli Lilly and Company (NYSE:LLY) by 34.5% during the fourth quarter, HoldingsChannel reports. The firm owned 8,025 shares of the company’s stock after selling 4,220 shares during the quarter. Cumberland Partners Ltd’s holdings in Eli Lilly and Company were worth $4,608,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Lipe & Dalton acquired a new position in shares of Eli Lilly and Company during the fourth quarter worth $26,000. Thompson Investment Management Inc. acquired a new stake in Eli Lilly and Company in the third quarter valued at $27,000. Legacy Financial Group LLC acquired a new stake in Eli Lilly and Company in the third quarter valued at $35,000. Optiver Holding B.V. acquired a new stake in Eli Lilly and Company in the third quarter valued at $36,000. Finally, Family CFO Inc acquired a new stake in Eli Lilly and Company in the third quarter valued at $40,000. 82.53% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Eli Lilly and Company

In related news, major shareholder Lilly Endowment Inc sold 54,032 shares of the stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total value of $34,854,422.24. Following the completion of the transaction, the insider now owns 99,488,598 shares in the company, valued at approximately $64,177,109,911.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 0.13% of the stock is currently owned by insiders.

Eli Lilly and Company Stock Performance

Shares of Eli Lilly and Company stock traded up $14.29 during trading on Tuesday, hitting $745.62. 2,041,595 shares of the stock were exchanged, compared to its average volume of 3,051,032. The stock’s fifty day moving average is $763.89 and its 200 day moving average is $664.05. The stock has a market cap of $708.46 billion, a PE ratio of 128.56, a P/E/G ratio of 1.58 and a beta of 0.34. The company has a debt-to-equity ratio of 1.69, a quick ratio of 0.73 and a current ratio of 0.94. Eli Lilly and Company has a 12 month low of $370.68 and a 12 month high of $800.78.

Eli Lilly and Company (NYSE:LLY) last announced its earnings results on Tuesday, February 6th. The company reported $2.49 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.19. The firm had revenue of $9.35 billion during the quarter, compared to analyst estimates of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. Eli Lilly and Company’s revenue was up 28.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.09 EPS. As a group, sell-side analysts anticipate that Eli Lilly and Company will post 12.52 EPS for the current year.

Analysts Set New Price Targets

Several research firms recently issued reports on LLY. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $815.00 price target on shares of Eli Lilly and Company in a report on Monday, April 15th. Citigroup upped their price target on shares of Eli Lilly and Company from $675.00 to $895.00 and gave the company a “buy” rating in a report on Tuesday, April 2nd. Barclays upped their price target on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the company an “overweight” rating in a report on Wednesday, February 7th. The Goldman Sachs Group boosted their target price on shares of Eli Lilly and Company from $650.00 to $723.00 and gave the company a “neutral” rating in a research note on Thursday, April 11th. Finally, Bank of America boosted their target price on shares of Eli Lilly and Company from $800.00 to $1,000.00 and gave the company a “buy” rating in a research note on Friday, March 1st. Three investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. Based on data from MarketBeat.com, Eli Lilly and Company has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.